Program
anifrolumab
Also written as “Anifrolumab”, “MEDI-546” and “Anifrolumab (blinded)”.
Its studies are mostly in Lupus Erythematosus, Systemic · Lupus Nephritis · Scleroderma, Systemic · Lupus Erythematosus, Cutaneous · Dermatomyositis, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 2512 open or running | phase 4since Sep 10, 2024 | Jun 29, 2009 | Jan 6, 2027phase 3 · NCT05925803 |
Also a collaborator on its studies: icon-plc, parexel, ppd-development-lp, iqvia-pty-ltd and pra-health-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jun 29, 2009.
- May 4, 2021Phase 3 study in Lupus Erythematosus, SystemicNCT04877691 · 367 enrolled · United States, Argentina, Bulgaria and more
- Jun 30, 2021Phase 1 study in Lupus Erythematosus, SystemicNCT05001698 · 15 enrolled · China
- Nov 17, 2021Phase 3 study in Lupus NephritisNCT05138133 · 363 enrolled · United States, Argentina, Belgium and more
- Apr 18, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT05835310 · 100 planned · United States, Argentina, Brazil and more
- Jun 2, 2023Phase 3 study in Scleroderma, SystemicNCT05925803 · 314 enrolled · United States, Austria, Belgium and more
- Aug 1, 2023Phase 3 study in Lupus Erythematosus, CutaneousNCT06015737 · 339 enrolled · United States, Argentina, Australia and more
- Sep 28, 2023Phase 3 study in DermatomyositisNCT06455449 · 240 planned · United States, Argentina, Australia and more
- Sep 4, 2024Phase 1 study in Healthy VolunteersNCT06662123 · 24 enrolled · China
- Sep 10, 2024Phase 4 study in Lupus Erythematosus, SystemicNCT06594068 · 16 planned · United States
- Feb 2, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07430306 · 245 planned · United States, Canada, France and more
- Jun 2, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07630714 · 24 planned · Australia, Belgium, Chile and more
- Jun 23, 2026Phase 3 study in Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusNCT07691970 · 1,072 planned · United States, Argentina, Australia and more
- Jun 30, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07688980 · 92 planned
- Jul 21, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07751848 · 417 planned · China
Ahead
- Nov 2, 2026Primary completion: phase 3 study in Lupus Erythematosus, CutaneousNCT06015737
- Jan 6, 2027Primary completion: phase 3 study in Scleroderma, SystemicNCT05925803
- Feb 23, 2027Primary completion: phase 3 study in Lupus NephritisNCT05138133
- Aug 31, 2027Primary completion: phase 4 study in Lupus Erythematosus, SystemicNCT06594068
TargetBeta
“Interferon-alpha/beta receptor alpha chain antagonist”ChEMBL 37, by rule
Other programs on IFNAR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| peginterferon alfa-2arule | Hoffmann-La Roche | phase 4 | 100 |
| Interferon beta-1arule | Biogen | phase 4 | 60 |
| peginterferon alfa-2brule | Merck | phase 4 | 56 |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 8 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07751848Lupus Erythematosus, Systemic · China | 3 | Recruiting | Aug 25, 2028 | 417 |
| NCT07688980Lupus Erythematosus, Systemic | 1 | Not yet recruiting | Apr 13, 2029 | 92 |
| NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus · United States, Argentina, Australia and more | 3 | Recruiting | Dec 30, 2032 | 1,072 |
| NCT07630714Lupus Erythematosus, Systemic · Australia, Belgium, Chile and more | 2 | Recruiting | Sep 2, 2030 | 24 |
| NCT07430306Lupus Erythematosus, Systemic · United States, Canada, France and more | 3 | Recruiting | Jan 26, 2029 | 245 |
| NCT06594068Lupus Erythematosus, Systemic · United States | 4 | Recruiting | Aug 31, 2027 | 16 |
| NCT06662123Healthy Volunteers · China | 1 | Completed | Jan 10, 2025 | 24 |
| NCT06455449Dermatomyositis · United States, Argentina, Australia and more | 3 | Recruiting | Jan 10, 2028 | 240 |
| NCT06015737Lupus Erythematosus, Cutaneous · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 2, 2026 | 339 |
| NCT05925803Scleroderma, Systemic · United States, Austria, Belgium and more | 3 | Active, not recruiting | Jan 6, 2027 | 314 |
| NCT05835310Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Recruiting | Oct 5, 2028 | 100 |
| NCT05138133Lupus Nephritis · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Feb 23, 2027 | 363 |
| NCT05001698Lupus Erythematosus, Systemic · China | 1 | Completed | Jun 2, 2022 | 15 |
| NCT04877691Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | Aug 22, 2025 | 367 |
| NCT04931563Active Systemic Lupus Erythematosus · China, Hong Kong, Philippines and more | 3 | Completed | Apr 7, 2025 | 277 |
| NCT02962960Lupus Erythematosus, Systemic · United States, Hungary, Korea, Republic of and more | 2 | Completed | Jan 22, 2018 | 36 |
| NCT02794285Connective Tissue Diseases · United States, Argentina, Australia and more | 3 | Completed | Dec 21, 2021 | 559 |
| NCT02601625Safety · United States | 1 | Completed | May 25, 2016 | 30 |
| NCT02547922Lupus Nephritis · United States, Argentina, Australia and more | 2 | Completed | Nov 26, 2019 | 147 |
| NCT02446912Active Systemic Lupus Erythematosus · United States, Argentina, Australia and more | 3 | Completed | Jul 17, 2018 | 460 |
| NCT02446899Active Systemic Lupus Erythematosus · United States, Argentina, Belgium and more | 3 | Completed | Sep 27, 2018 | 373 |
| NCT01753193Lupus Erythematosus, Systemic · United States, Brazil, Bulgaria and more | 2 | Completed | Jul 18, 2018 | 218 |
| NCT01559090Lupus Erythematosus, Systemic · Japan | 2 | Completed | Aug 19, 2014 | 17 |
| NCT01438489Lupus Erythematosus, Systemic · United States, Brazil, Bulgaria and more | 2 | Completed | Apr 2015 | 626 |
| NCT00930683Scleroderma, Diffuse · United States | 1 | Completed | May 2010 | 34 |
How it is read
Names in the registry
- “Anifrolumab”, 18 entries
- “MEDI-546”, 12 entries
- “Anifrolumab (blinded)”, 2 entries
- “Anifrolumab (unblinded, open label)”, 2 entries
- “Anifrolumab + APFS”, 1 entry
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 16 studies
- Lupus Nephritis, 2 studies
- Scleroderma, Systemic, 1 study
- Lupus Erythematosus, Cutaneous, 1 study
- Dermatomyositis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.